Product Description

Recombinant 2019-nCoV NSP1 is produced by our E.coli expression system and the target gene encoding Met1-Gly180 is expressed with a 6His tag at the C-terminus.Background:The Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV) is an enveloped, positive-stranded RNA viruses that can cause a severe respiratory disease. Its genome consists of a ∼30 kb linear, non-segmented, capped, polycistronic, polyadenylated RNA molecule, the first two-third of which is directly translated into two large polyproteins. These two polypeptides are processed into 16 non-structural proteins (nsps), forming the replicase complex, which is active in the cytoplasm in close association with cellular membranes. Nsp1 was proved to be able to suppress host gene expression by promoting host mRNA degradation and was involved in cellular chemokine deregulation. This virus evades the host innate immune response in part through the expression of its non-structural protein (nsp) 1, which inhibits both host gene expression and virus- and interferon (IFN)-dependent signaling. Thus, nsp1 is a promising target for drugs, as inhibition of nsp1 would make SARS-CoV more susceptible to the host antiviral defenses.Formulation:Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 10% Glycerol, pH 8.5.Purity:> 85 % as determined by reducing SDS-PAGE.Endotoxin:< 1.0 EU per µg as determined by the LAL method.Shipping:This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at<-20°C. Avoid freeze-thaw cycles.

More Details:Sequence:Met1-Gly180Fusion Tag:C-6HisAccession:YP_009725297.1Species:VirusExpression System:E. coliMol Mass:22.7 kDaAP Mol Mass:25 kDaSynonyms:SARS-CoV 2 nsp1; SARS-CoV 2 Leader proteinDatasheet

FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES.Manufactured by: Elabscience

Questions about this product? Ready to place an order? Email us atorders@iwai-chem.comor give us a call: (650) 486-1541

Iwai-Chem我们的合作伙伴公司Bio Matrix Research，Inc.（BMR）正在申请专利，CELIXSYS™是一种新颖的单克隆抗体筛选方法（免疫沉淀等效系统），可保持抗原构象完整且表位不受空间位阻。  通过克服传统的基于固相的筛选方法（例如抗原包被的ELISA，斑点印迹或蛋白质印迹）的缺点，CELIXSYS™使我们能够获得适用于各种应用的卓越单克隆抗体，例如高灵敏度夹心ELISA，免疫色谱法或抗体阵列系统，以及免疫沉淀和蛋白质印迹。CELIXSYS™使得开发有益的单克隆抗体成为可能，而迄今为止，传统方法尚无法实现。展望未来，这项新技术的应用领域将继续从基础研究和临床诊断试剂扩展到抗体药物的探索。